Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.55 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL28366079 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL28366077 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL626780 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2069640 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21647170 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL22320723 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL1745993 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20492652 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL22320722 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL29635022 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260145365-A1 | METHOD AND DEVICE FOR PRODUCING A STABILIZER COMPOSITION IN GRANULATE FORM AND AN ACCORDINGLY PRODUCED STABILIZER COMPOSITION | AKDENIZ CHEMSON ADDITIVES A.G. (AT) | 2026-05-28 | — | — | US | disclosed |
| EP-4687504-A1 | ORAL COMPOSITIONS AND METHODS OF MANUFACTURE | Nicoventures Trading Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12507725-B2 | Translucent smokeless tobacco product | R.J. REYNOLDS TOBACCO COMPANY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4605200-A1 | METHOD AND DEVICE FOR PRODUCING A STABILIZER COMPOSITION IN GRANULATE FORM AND AN ACCORDINGLY PRODUCED STABILIZER COMPOSITION | Akdeniz Chemson Additives AG (AT) | 2025-08-27 | — | — | EP | disclosed |
| US-20250235406-A1 | ORAL PRODUCTS AND METHODS OF MANUFACTURE | NICOVENTURES TRADING LTD (GB) | 2025-07-24 | — | — | US | disclosed |
| US-12171872-B2 | Oral compositions and methods of manufacture | Nicoventures Trading Limited (GB) | 2024-12-24 | — | — | US | disclosed |
| WO-2024201343-A1 | ORAL COMPOSITIONS AND METHODS OF MANUFACTURE | Nicoventures Trading Limited (GB) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024175568-A1 | STABILIZING COMPOSITION FOR HALOGEN-CONTAINING POLYMERS | REAGEN S.P.A. (IT) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024175174-A1 | STABILIZING COMPOSITION FOR HALOGEN-CONTAINING POLYMERS | REAGENS S.P.A. (IT) | 2024-08-29 | — | — | WO | disclosed |
| US-20240165866-A1 | METHOD FOR PRODUCING A STABILISER COMPOSITION FOR A POLYMER, AND STABILISER COMPOSITION PRODUCED USING SAID METHOD | AKDENIZ CHEMSON ADDITIVES AG (AT) | 2024-05-23 | — | — | US | disclosed |
| US-20130152953-A1 | SMOKELESS TOBACCO PRODUCT COMPRISING EFFERVESCENT COMPOSITION | R. J. REYNOLDS TOBACCO COMPANY | 2013-06-20 | — | — | US | disclosed |
| US-20130078307-A1 | NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITION | NICONOVUM USA, INC. | 2013-03-28 | — | — | US | disclosed |
| CN-101107304-B | Method for shaping stabilizer melts into pastilles, shaped bodies produced accordingly and the use thereof | BAERLOCHER GMBH | 2011-06-08 | — | — | CN | disclosed |
| US-20090280172-A1 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | CARRENO-GOMEZ BEGONA | 2009-11-12 | — | — | US | disclosed |
| CN-101505724-A | Galenic formulations of aliskiren | NOVARTIS AG (CH) | 2009-08-12 | — | — | CN | disclosed |
| EP-2056790-A2 | GALENIC FORMULATIONS OF ALISKIREN | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008065144-A2 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008023016-A2 | GALENIC FORMULATIONS OF ALISKIREN | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| EP-1891937-A1 | Galenic formulations of aliskiren | Novartis AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| CN-101107304-A | Method for shaping stabilizer melts into pastilles, shaped bodies produced accordingly and the use thereof | BAERLOCHER GMBH (DE) | 2008-01-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280172-A1 | GALENIC FORMULATIONS OF ORGANIC COMPOUNDS | GALK1, GALR2, GALR1 | PDE4A 3908/4885TOP1 4409/4885LMNA 1162/4885 |
| US-12507725-B2 | Translucent smokeless tobacco product | SLC6A12, SLC6A6, ICMT | PDE4A 3100/4885TOP1 3919/4885LMNA 2826/4885 |
| US-20260145365-A1 | METHOD AND DEVICE FOR PRODUCING A STABILIZER COMPOSITION IN GRANULATE FORM AND AN ACCORDINGLY PRODUCED STABILIZER COMPOSITION | GRN, IL36G, GMNN | PDE4A 4552/4885TOP1 1127/4885LMNA 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.